Back
Karyopharm Therapeutics, Inc. 10K Form
Sell
34
KPTI
Karyopharm Therapeutics, Inc.
Last Price:
$5.88
Seasonality Move:
12.63%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-08 | 10Q | KPTI/Karyopharm Therapeutics, Inc. Quarterly |
| 2023-11-02 | 10Q | KPTI/Karyopharm Therapeutics, Inc. Quarterly |
| 2023-08-02 | 10Q | KPTI/Karyopharm Therapeutics, Inc. Quarterly |
| 2023-05-04 | 10Q | KPTI/Karyopharm Therapeutics, Inc. Quarterly |
| 2022-11-03 | 10Q | KPTI/Karyopharm Therapeutics, Inc. Quarterly |
| 2022-08-04 | 10Q | KPTI/Karyopharm Therapeutics, Inc. Quarterly |
Receive KPTI News And Ratings
See the #1 stock for the next 7 days that we like better than KPTI
KPTI Financial Statistics
Sales & Book Value
| Annual Sales: | $145.2M |
|---|---|
| Cash Flow: | $-5.9M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-30.94 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -14.58070 |
|---|---|
| Net Income (TTM): | $-124.6M |
| Gross Margin: | $138.9M |
| Return on Equity: | 0% |
| Return on Assets: | -91.27% |
Karyopharm Therapeutics, Inc. Earnings Forecast
Key Karyopharm Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 14 years for KPTI is 95.63%.
-
The Selling, General & Administrative Expenses for KPTI have been equal to 79.48% of Gross Profit Margin.
-
The Research & Development expenses have been 98.39% of Revenue.
-
The Net Earning history of KPTI is -52.62% of Total Revenues.
-
Per Share Earnings over the last 14 years have been positive in 6 years.
Karyopharm Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | KPTI |
| CUSIP: | 48576U |
| Website: | karyopharm.com |
Debt
| Debt-to-Equity Ratio: | -0.73 |
|---|---|
| Current Ratio: | 1.03 |
| Quick Ratio: | 0.89 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
KPTI Technical Analysis vs Fundamental Analysis
Sell
34
Karyopharm Therapeutics, Inc. (KPTI)
is a Sell
Is Karyopharm Therapeutics, Inc. a Buy or a Sell?
-
Karyopharm Therapeutics, Inc. stock is rated a SellThe current Karyopharm Therapeutics, Inc. [KPTI] share price is $5.91. The Score for KPTI is 34, which is 32% below its historic median score of 50, and infers higher risk than normal.